$INTI
Inhibitor Therapeutics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000119312520129857 Filed on May 01, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $262.4K $288.0K $594.8K
YoY Change -20.95% -51.58% 18.97%
% of Gross Profit
Research & Development $52.66K $97.46K $196.8K
YoY Change -82.65% -50.47% -70.8%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $315.0K $385.4K $791.6K
YoY Change -50.43% -51.31% -32.62%
Operating Profit -$315.0K -$385.4K -$791.6K
YoY Change -50.43% -51.31% -32.62%
Interest Expense $150.00 $1.030K $5.310K
YoY Change -94.66% -80.6%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$314.9K -$384.4K -$786.3K
YoY Change -50.23% -51.11% -32.8%
Income Tax
% Of Pretax Income
Net Earnings -$314.9K -$384.4K -$786.3K
YoY Change -50.23% -51.11% -32.83%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$850.00 -$1.038K -$2.123K
COMMON SHARES
Basic Shares Outstanding 370.4M 370.4M 370.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $137.3K $302.7K $1.131M
YoY Change -93.22% -73.23% -27.98%
Cash & Equivalents $137.3K $302.7K $1.131M
Short-Term Investments
Other Short-Term Assets $40.03K $48.24K $46.15K
YoY Change 5.31% 4.53% -84.62%
Inventory
Prepaid Expenses $40.03K $48.24K $46.15K
Receivables
Other Receivables
Total Short-Term Assets $177.3K $350.9K $1.177M
YoY Change -91.4% -70.18% -37.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $39.05K $46.38K $75.67K
YoY Change -42.86% -38.71% -27.91%
Total Long-Term Assets $39.05K $46.38K $75.67K
YoY Change -42.86% -38.71% -27.91%
TOTAL ASSETS
Total Short-Term Assets $177.3K $350.9K $1.177M
Total Long-Term Assets $39.05K $46.38K $75.67K
Total Assets $216.4K $397.3K $1.253M
YoY Change -89.85% -68.28% -36.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $158.5K $154.2K $245.2K
YoY Change -18.86% -37.08% -33.76%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $16.18K $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $461.6K $345.9K $324.8K
YoY Change 51.45% 6.49% -26.37%
LONG-TERM LIABILITIES
Long-Term Debt $25.42K $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $1.500M
YoY Change 0.0% 100.0%
Total Long-Term Liabilities $3.025M $3.000M $1.500M
YoY Change 0.85% 100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $461.6K $345.9K $324.8K
Total Long-Term Liabilities $3.025M $3.000M $1.500M
Total Liabilities $3.487M $3.346M $1.825M
YoY Change 5.51% 83.36% 313.64%
SHAREHOLDERS EQUITY
Retained Earnings -$56.71M -$56.35M -$53.82M
YoY Change 4.06% 4.7% 8.78%
Common Stock $49.48M $49.44M $49.28M
YoY Change 0.24% 0.32% -3.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.271M -$2.949M -$572.3K
YoY Change
Total Liabilities & Shareholders Equity $216.4K $397.3K $1.253M
YoY Change -89.85% -68.28% -36.73%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$314.9K -$384.4K -$786.3K
YoY Change -50.23% -51.11% -32.83%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$207.0K -$501.1K -$978.0K
YoY Change -65.82% -48.76% -13.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 41.60K 0.000 1.000M
YoY Change -97.23% -100.0% -57.64%
NET CHANGE
Cash From Operating Activities -207.0K -501.1K -978.0K
Cash From Investing Activities
Cash From Financing Activities 41.60K 0.000 1.000M
Net Change In Cash -165.4K -501.1K 22.01K
YoY Change -118.49% -2376.72% -98.21%
FREE CASH FLOW
Cash From Operating Activities -$207.0K -$501.1K -$978.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
154240
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
315940
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49401772
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49384953
CY2020Q1 us-gaap Assets
Assets
397304
CY2019Q4 us-gaap Assets
Assets
899966
CY2020Q1 us-gaap Assets Current
AssetsCurrent
350927
CY2019Q4 us-gaap Assets Current
AssetsCurrent
846266
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
302688
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803816
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
37045
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37045
CY2020Q1 us-gaap Liabilities
Liabilities
3345900
CY2019Q4 us-gaap Liabilities
Liabilities
3431101
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
397304
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
899966
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
345900
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
431101
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
46377
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53700
CY2020Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
40975
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14339
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
48239
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42450
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56348279
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55913999
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-2948596
CY2020Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
150685
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2020Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-384417
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-791600
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1025
CY2019Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5312
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-385442
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370389855
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97455
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
196774
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
287987
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
594826
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
385442
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
791600
CY2020Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
CY2020Q1 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-434280
CY2019Q1 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-835603
CY2019Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49315
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2531135
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
16819
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
131031
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2019Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-384417
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-786288
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16819
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
131031
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1534
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2467
CY2020Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-135064
CY2019Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-325199
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-501128
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-977989
CY2020Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-501128
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
22011
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1130724
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2020Q1 inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49863
CY2019Q1 inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49315
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1000000
CY2019Q1 us-gaap Stock Issued1
StockIssued1
99946
CY2019Q1 inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
1000000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370446185
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
CY2020Q1 us-gaap Revenues
Revenues
0
CY2019Q1 us-gaap Revenues
Revenues
0
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2020Q1 inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
0
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2020Q1 us-gaap Stock Issued1
StockIssued1
0

Files In Submission

Name View Source Status
0001193125-20-129857-index-headers.html Edgar Link pending
0001193125-20-129857-index.html Edgar Link pending
0001193125-20-129857.txt Edgar Link pending
0001193125-20-129857-xbrl.zip Edgar Link pending
d905457d10q.htm Edgar Link pending
d905457dex311.htm Edgar Link pending
d905457dex312.htm Edgar Link pending
d905457dex321.htm Edgar Link pending
d905457dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inti-20200331.xml Edgar Link completed
inti-20200331.xsd Edgar Link pending
inti-20200331_cal.xml Edgar Link unprocessable
inti-20200331_def.xml Edgar Link unprocessable
inti-20200331_lab.xml Edgar Link unprocessable
inti-20200331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending